Related Experiment Video
Updated: Mar 3, 2026
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Is antiplatelet treatment effective at attenuating the progression of white matter hyperintensities?
Cindy W Yoon1, Yoonjae Choi1, Seun Jeon2
1Department of Neurology, Inha University School of Medicine, Incheon, Korea.
Objective:
We performed this study to assess the effect of an antiplatelet agent on the progression of white matter hyperintensities (WMH).
Methods:
From August 2003 to May 2005, we consecutively enrolled patients who underwent brain magnetic resonance imaging (MRI) for health check-up purposes and showed no significant findings other than WMH of any degree. Patients were divided into two groups based on whether or not they received antiplatelet therapy. All patients had a follow-up brain MRI after 5 years and WMH volume change was measured using imaging analysis software. To minimize selection bias potentially arising from antiplatelet treatment assignment, analyses were inverse probability weighted.
Results:
Among the 93 patients who met the inclusion criteria, 54 patients (58.1%) were grouped as the antiplatelet group (AG), and the remaining 39 patients (41.9%) as the non-antiplatelet group (NAG). After inverse propensity weighting, all baseline characteristics were similar between the two groups, and antiplatelet treatment did not show any significant effect on the total WMH volume change (p = 0.957).
Conclusion:
Antiplatelet medication may not alter the progression of WMH.
Insights
This study found that antiplatelet agents did not significantly alter the progression of white matter hyperintensities (WMH) over five years. These findings suggest antiplatelet medication may not impact WMH volume changes.
Area of Science:
- Neurology
- Radiology
- Pharmacology
Background:
- White matter hyperintensities (WMH) are common findings on brain MRI, associated with aging and cerebrovascular disease.
- Understanding factors influencing WMH progression is crucial for managing cognitive decline and stroke risk.
Purpose of the Study:
- To evaluate the impact of antiplatelet therapy on the progression of white matter hyperintensities (WMH).
Main Methods:
- A cohort of 93 patients with WMH on baseline brain MRI were followed for 5 years.
- Patients were divided into antiplatelet (n=54) and non-antiplatelet (n=39) groups.
- Inverse probability weighting was used to minimize selection bias; WMH volume change was measured via MRI analysis.
Main Results:
- After propensity weighting, baseline characteristics were similar between groups.
- Antiplatelet treatment showed no significant effect on the change in total WMH volume (p = 0.957).
Conclusions:
- Antiplatelet medication does not appear to significantly alter the progression of white matter hyperintensities.
- Further research may be needed to explore other therapeutic strategies for WMH management.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:22Alzheimer's Disease: Treatment
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:29Venous Thrombosis III: Interprofessional Care